BRIEF published on 06/03/2024 at 07:35, 2 years 3 months ago GenSight Biologics Welcomes William Monteith to the Board of Directors Board Of Directors Nomination GenSight Biologics William Monteith Gene Therapies
PRESS RELEASE published on 06/03/2024 at 07:30, 2 years 3 months ago Informations privilégiées / Autres communiqués GenSight Biologics nomme William Monteith à son Conseil d'administration. Monteith apportera son expertise en fabrication de thérapies géniques pour soutenir les progrès de l'entreprise Conseil D'administration Fabrication GenSight Biologics Thérapies Géniques William Monteith
BRIEF published on 05/23/2024 at 11:40, 2 years 3 months ago Franchissement de seuils pour GENSIGHT BIOLOGICS S.A. Actions Franchissement De Seuils Bons De Souscription GenSight Biologics Armistice Capital
BRIEF published on 05/23/2024 at 11:40, 2 years 3 months ago Crossing thresholds for GENSIGHT BIOLOGICS SA Actions Crossing Thresholds GenSight Biologics Armistice Capital Subscription Warrants
PRESS RELEASE published on 05/23/2024 at 11:35, 2 years 3 months ago Franchissement de seuils Déclaration de franchissement de seuils par Armistice Capital, LLC concernant GENSIGHT BIOLOGICS S.A. sur Euronext Paris Euronext Paris Franchissement De Seuils Armistice Capital LLC GENSIGHT BIOLOGICS SA Déclaration Régularisation
BRIEF published on 05/07/2024 at 19:34, 2 years 4 months ago GenSight Biologics Announces Availability of Prospectus for New Shares Listing on Euronext Paris Euronext Paris Capital Increase Gene Therapy Prospectus GenSight Biologics
BRIEF published on 05/07/2024 at 19:34, 2 years 4 months ago GenSight Biologics annonce la mise à disposition d'un prospectus pour la cotation de nouvelles actions sur Euronext Paris Euronext Paris Augmentation De Capital Thérapie Génique Prospectus Produits Biologiques GenSight
PRESS RELEASE published on 05/07/2024 at 19:29, 2 years 4 months ago Terms of availability of prospectuses GenSight Biologics announces availability of listing prospectus for new shares on Euronext Paris. The prospectus approved by AMF includes universal registration document, securities note, and summary Euronext Paris New Shares AMF Approval GenSight Biologics Listing Prospectus
PRESS RELEASE published on 05/07/2024 at 19:29, 2 years 4 months ago Modalités de mise à disposition de prospectus GenSight Biologics annonce la mise à disposition d'un prospectus pour l'admission d'actions nouvelles sur Euronext Paris. La société spécialisée dans les thérapies géniques pour les maladies neurodégénératives informe sur le processus Euronext Paris Prospectus GenSight Biologics Thérapies Géniques Maladies Neurodégénératives
Published on 09/10/2026 at 22:25, 3 hours 38 minutes ago Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 15:20, 10 hours 43 minutes ago MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 11 hours 3 minutes ago All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
Published on 09/10/2026 at 14:37, 11 hours 26 minutes ago Worksport (NASDAQ:WKSP) Invites Shareholders to September 15 CEO Town Hall
Published on 09/11/2026 at 00:05, 1 hour 57 minutes ago Club Offers for Travel Enthusiasts in Germany
Published on 09/11/2026 at 00:01, 2 hours 2 minutes ago Club Offers for Travel Enthusiasts in Germany
Published on 09/10/2026 at 22:39, 3 hours 23 minutes ago EQS-Adhoc: Notice by Rumble Deutschland AG regarding an upcoming squeeze-out under German Stock Corporation Law
Published on 09/10/2026 at 22:10, 3 hours 52 minutes ago flatexDEGIRO with changes to the Supervisory Board
Published on 09/10/2026 at 22:07, 3 hours 56 minutes ago EQS-Adhoc: flatexDEGIRO SE: Changes to the Supervisory Board
Published on 09/10/2026 at 19:30, 6 hours 33 minutes ago Availability of the 2026 Interim Financial Report
Published on 09/10/2026 at 19:30, 6 hours 33 minutes ago Mise à disposition du Rapport Financier Semestriel 2026
Published on 09/10/2026 at 18:10, 7 hours 53 minutes ago LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 août 2026
Published on 09/10/2026 at 17:45, 8 hours 18 minutes ago COGRA : RÉSULTATS ANNUELS 2025/26 - Retour à la croissance rentable et structure financière renforcée
Published on 09/10/2026 at 17:42, 8 hours 20 minutes ago Déclaration d'actions et de droits de vote au 31.08.2026
